Cargando…
High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India
BACKGROUND: The information on seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among patients with inflammatory bowel disease (IBD) and its comparison to healthy controls is sparse. We compared the seroprevalence rates in patients with IBD and healthy control...
Autores principales: | Kante, Bhaskar, Vuyyuru, Sudheer Kumar, Gupta, Ritu, Dwivedi, Tanima, Kumar, Peeyush, Mundhra, Sandeep, Golla, Rithvik, Virmani, Shubi, Verma, Mahak, Makharia, Govind, Ahuja, Vineet, Kedia, Saurabh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898695/ https://www.ncbi.nlm.nih.gov/pubmed/36738383 http://dx.doi.org/10.1007/s12664-022-01310-y |
Ejemplares similares
-
Su1075: SIMILAR RISK OF INFECTION WITH SARS-COV-2 IN IMMUNOCOMPROMISED AND IMMUNOCOMPETENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEALTHY CONTROLS
por: Kante, Bhaskar, et al.
Publicado: (2022) -
Long-term Gastrointestinal Sequelae Following COVID-19: A Prospective Follow-up Cohort Study
por: Golla, Rithvik, et al.
Publicado: (2023) -
Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring
por: Kumar, Peeyush, et al.
Publicado: (2023) -
Interferon-gamma release assay has poor diagnostic accuracy in differentiating intestinal tuberculosis from Crohn’s disease in tuberculosis endemic areas
por: Sachdeva, Karan, et al.
Publicado: (2023) -
Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
por: Vuyyuru, Sudheer K., et al.
Publicado: (2021)